John Rim
{{#set:Bad_content=reason }} {{#set:Bad_content= }}
John Rim (born John Chongbo Rim) is a Korean-American business executive. He is the President and chief executive officer (CEO) of Samsung Biologics.[1]
John earned his undergraduate degree from Columbia University in chemical engineering. He attained a M.S. from Stanford University in chemical engineering, then pivoting into business and pursued a MBA from the Kellogg School of Management.[2]
He began his career as a management consultant at Booz, Allen& Hamilton, consulting to pharmaceutical companies in the US and across Europe. Prior to working at Samsung Biologics, John held senior global leadership roles in finance, product development, and R&D working at Roche Holding companies.[3]
Before being appointed CEO, he served as the executive vice president at Samsung Biologics. John was a pivotal person in expanding the manufacturing portfolio with the opening of Plant 3, the world's largest manufacturing capacity at a single site. He closely manages its first overseas contract development organization laboratory in South San Francisco.[4][5] John will lead Samsung Biologics with a global diversification strategy, pushing manufacturing into the U.S, then Europe and eventually, China. Under the leadership of John, Samsung Biologics is now valued at $45.90 Billion.[6]
Career[edit]
Speaking at the 29th annual JP Morgan Healthcare Conference, John revealed the company's growth plans. The company's biggest project for 2021 will be to accelerate the construction of Plant 4 to boost manufacturing capacity by 70%.[7]
In May 2021, John and President Moon Jae-In departed for the Biden-Moon summit in the United States to sign a deal to manufacture Moderna's COVID-19 vaccine at its local factory[8]. Samsung Biologics agreed to support filling in vials and packaging of the drug.[9] Under the contract, Samsung will roll out hundreds of millions of doses of the COVID-19 vaccine starting in the third quarter of 2021.[10]
Reference section[edit]
- ↑ Biologics, Samsung. "Samsung Biologics Names John Rim as President and CEO". www.prnewswire.com. Retrieved 2021-10-08.
- ↑ 김한주 (2020-12-08). "Samsung Biologics names John Rim new CEO". Yonhap News Agency. Retrieved 2021-10-08.
- ↑ "Samsung Biologics promotes new CEO from within to head next phase of rapid manufacturing expansion". Endpoints News. Retrieved 2021-10-08.
- ↑ "John Rim becomes president and CEO of Samsung Biologics". www.thepharmaletter.com. Retrieved 2021-10-08.
- ↑ "[INTERVIEW] K-biopharm exec on overseas expansion, global strategy". koreajoongangdaily.joins.com. Retrieved 2021-10-08.
- ↑ "Samsung Biologics (207940.KS) - Market capitalization". companiesmarketcap.com. Retrieved 2021-10-08.
- ↑ "Samsung Biologics speeds $2B plant build forecast to boost capacity 70%". FiercePharma. Retrieved 2021-10-08.
- ↑ 이치동 (2021-05-23). "(LEAD) Samsung Biologics signs vaccine production deal with Moderna". Yonhap News Agency. Retrieved 2021-10-08.
- ↑ Herald, Korea (2021-05-23). "[Newsmaker] Samsung Biologics sets out preparation for Moderna vaccine production". The Korea Herald. Retrieved 2021-10-08.
- ↑ "Samsung on course to produce Moderna vaccine: CEO". koreatimes. 2021-06-16. Retrieved 2021-10-08.
External links section[edit]
{{#set:Technical tag=Article from Wikipedia}}{{#set:priority= }} {{#set:PageName=John_Rim }}
This article "John Rim" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:John Rim. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.{{#set:Article=true}}
